Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORRECT: Contact Radiotherapy for Rectal Cancer
NCT06501053Recruiting
- Start
- Mar 2025
- Primary completion
- Apr 2030
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in rectal cancer (2 arms). Primary endpoint: Rectum preservation at 24 months. Started Mar 2025; status: recruiting.
02
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06501053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06501053.